ASH News Daily 2017 - Issue 1 - B-56

The first and only oral proteasome inhibitor

EFFICACY.

EXTENDED.
The approval of the NINLARO® (ixazomib) regimen (NINLARO+lenalidomide+
dexamethasone) was based on a statistically significant ~6 month improvement
in median PFS vs the placebo regimen (placebo+lenalidomide+dexamethasone)
in patients with relapsed and/or refractory multiple myeloma.*
* Median PFS: 20.6 vs 14.7 months (95% CI, 17.0-NE and 95% CI, 12.9-17.6,
respectively); HR=0.74 (95% CI, 0.587-0.939); P=0.012

NINLARO is indicated in combination with lenalidomide and dexamethasone
for the treatment of patients with multiple myeloma who have received at
least one prior therapy.

Find out more at booth #2014, and see what the experts
are saying at NINLAROhcp.com.

IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
* Thrombocytopenia has been reported with NINLARO. During treatment, monitor platelet counts at least monthly, and
consider more frequent monitoring during the first three cycles. Manage thrombocytopenia with dose modifications
and platelet transfusions as per standard medical guidelines. Adjust dosing as needed. Platelet nadirs occurred
between Days 14-21 of each 28-day cycle and typically recovered to baseline by the start of the next cycle.
* Gastrointestinal Toxicities, including diarrhea, constipation, nausea and vomiting, were reported with NINLARO and
may occasionally require the use of antidiarrheal and antiemetic medications, and supportive care. Diarrhea resulted in
the discontinuation of one or more of the three drugs in 1% of patients in the NINLARO regimen and < 1% of patients
in the placebo regimen. Adjust dosing for severe symptoms.
* Peripheral Neuropathy (predominantly sensory) was reported with NINLARO. The most commonly reported reaction
was peripheral sensory neuropathy (19% and 14% in the NINLARO and placebo regimens, respectively). Peripheral
motor neuropathy was not commonly reported in either regimen (< 1%). Peripheral neuropathy resulted in
discontinuation of one or more of the three drugs in 1% of patients in both regimens. Monitor patients for symptoms of
peripheral neuropathy and adjust dosing as needed.
Please see next page for additional NINLARO (ixazomib) Important Safety Information and Brief Summary on
subsequent pages.



Table of Contents for the Digital Edition of ASH News Daily 2017 - Issue 1

ASH News Daily 2017 - Issue 1 - A-1
ASH News Daily 2017 - Issue 1 - A-2
ASH News Daily 2017 - Issue 1 - A-3
ASH News Daily 2017 - Issue 1 - A-4
ASH News Daily 2017 - Issue 1 - A-5
ASH News Daily 2017 - Issue 1 - A-6
ASH News Daily 2017 - Issue 1 - A-7
ASH News Daily 2017 - Issue 1 - A-8
ASH News Daily 2017 - Issue 1 - A-9
ASH News Daily 2017 - Issue 1 - A-10
ASH News Daily 2017 - Issue 1 - A-11
ASH News Daily 2017 - Issue 1 - A-12
ASH News Daily 2017 - Issue 1 - A-13
ASH News Daily 2017 - Issue 1 - A-14
ASH News Daily 2017 - Issue 1 - A-15
ASH News Daily 2017 - Issue 1 - A-16
ASH News Daily 2017 - Issue 1 - A-17
ASH News Daily 2017 - Issue 1 - A-18
ASH News Daily 2017 - Issue 1 - A-19
ASH News Daily 2017 - Issue 1 - A-20
ASH News Daily 2017 - Issue 1 - A-21
ASH News Daily 2017 - Issue 1 - A-22
ASH News Daily 2017 - Issue 1 - A-23
ASH News Daily 2017 - Issue 1 - A-24
ASH News Daily 2017 - Issue 1 - A-25
ASH News Daily 2017 - Issue 1 - A-26
ASH News Daily 2017 - Issue 1 - A-27
ASH News Daily 2017 - Issue 1 - A-28
ASH News Daily 2017 - Issue 1 - B-1
ASH News Daily 2017 - Issue 1 - B-2
ASH News Daily 2017 - Issue 1 - B-3
ASH News Daily 2017 - Issue 1 - B-4
ASH News Daily 2017 - Issue 1 - B-5
ASH News Daily 2017 - Issue 1 - B-6
ASH News Daily 2017 - Issue 1 - B-7
ASH News Daily 2017 - Issue 1 - B-8
ASH News Daily 2017 - Issue 1 - B-9
ASH News Daily 2017 - Issue 1 - B-10
ASH News Daily 2017 - Issue 1 - B-11
ASH News Daily 2017 - Issue 1 - B-12
ASH News Daily 2017 - Issue 1 - B-13
ASH News Daily 2017 - Issue 1 - B-14
ASH News Daily 2017 - Issue 1 - B-15
ASH News Daily 2017 - Issue 1 - B-16
ASH News Daily 2017 - Issue 1 - B-17
ASH News Daily 2017 - Issue 1 - B-18
ASH News Daily 2017 - Issue 1 - B-19
ASH News Daily 2017 - Issue 1 - B-20
ASH News Daily 2017 - Issue 1 - B-21
ASH News Daily 2017 - Issue 1 - B-22
ASH News Daily 2017 - Issue 1 - B-23
ASH News Daily 2017 - Issue 1 - B-24
ASH News Daily 2017 - Issue 1 - B-25
ASH News Daily 2017 - Issue 1 - B-26
ASH News Daily 2017 - Issue 1 - B-27
ASH News Daily 2017 - Issue 1 - B-30
ASH News Daily 2017 - Issue 1 - B-31
ASH News Daily 2017 - Issue 1 - B-32
ASH News Daily 2017 - Issue 1 - B-33
ASH News Daily 2017 - Issue 1 - B-34
ASH News Daily 2017 - Issue 1 - B-35
ASH News Daily 2017 - Issue 1 - B-36
ASH News Daily 2017 - Issue 1 - B-37
ASH News Daily 2017 - Issue 1 - B-38
ASH News Daily 2017 - Issue 1 - B-39
ASH News Daily 2017 - Issue 1 - B-40
ASH News Daily 2017 - Issue 1 - B-41
ASH News Daily 2017 - Issue 1 - B-42
ASH News Daily 2017 - Issue 1 - B-43
ASH News Daily 2017 - Issue 1 - B-44
ASH News Daily 2017 - Issue 1 - B-45
ASH News Daily 2017 - Issue 1 - B-46
ASH News Daily 2017 - Issue 1 - B-47
ASH News Daily 2017 - Issue 1 - B-48
ASH News Daily 2017 - Issue 1 - B-49
ASH News Daily 2017 - Issue 1 - B-50
ASH News Daily 2017 - Issue 1 - B-51
ASH News Daily 2017 - Issue 1 - B-52
ASH News Daily 2017 - Issue 1 - B-53
ASH News Daily 2017 - Issue 1 - B-54
ASH News Daily 2017 - Issue 1 - B-55
ASH News Daily 2017 - Issue 1 - B-56
ASH News Daily 2017 - Issue 1 - C-1
ASH News Daily 2017 - Issue 1 - C-2
ASH News Daily 2017 - Issue 1 - C-3
ASH News Daily 2017 - Issue 1 - C-4
ASH News Daily 2017 - Issue 1 - C-5
ASH News Daily 2017 - Issue 1 - C-6
ASH News Daily 2017 - Issue 1 - C-7
ASH News Daily 2017 - Issue 1 - C-8
ASH News Daily 2017 - Issue 1 - C-9
ASH News Daily 2017 - Issue 1 - C-10
ASH News Daily 2017 - Issue 1 - C-11
ASH News Daily 2017 - Issue 1 - C-12
ASH News Daily 2017 - Issue 1 - C-13
ASH News Daily 2017 - Issue 1 - C-14
ASH News Daily 2017 - Issue 1 - C-15
ASH News Daily 2017 - Issue 1 - C-16
ASH News Daily 2017 - Issue 1 - C-17
ASH News Daily 2017 - Issue 1 - C-18
ASH News Daily 2017 - Issue 1 - C-19
ASH News Daily 2017 - Issue 1 - C-20
ASH News Daily 2017 - Issue 1 - C-21
ASH News Daily 2017 - Issue 1 - C-22
ASH News Daily 2017 - Issue 1 - C-23
ASH News Daily 2017 - Issue 1 - C-24
ASH News Daily 2017 - Issue 1 - C-25
ASH News Daily 2017 - Issue 1 - C-26
ASH News Daily 2017 - Issue 1 - C-27
ASH News Daily 2017 - Issue 1 - C-28
ASH News Daily 2017 - Issue 1 - C-29
ASH News Daily 2017 - Issue 1 - C-30
ASH News Daily 2017 - Issue 1 - C-31
ASH News Daily 2017 - Issue 1 - C-32
https://www.nxtbookmedia.com